United States · FDA National Drug Code directory

Adbry

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
50222-346_8abedac8-f75e-42a0-8591-10fabcf41fb5
Product NDC
50222-346
Form
INJECTION, SOLUTION
Composition / generic term
tralokinumab-ldrm
Labeler
LEO Pharma Inc.
Marketing category
BLA
Marketing start / end (source format)
20220102
Source listing expiry
20261231

Source-listed ingredients

  • TRALOKINUMAB — 150 mg/mL

These values do not establish equivalence or a dose recommendation.

Packages

  • 2 SYRINGE, GLASS in 1 CARTON (50222-346-02) / 1 mL in 1 SYRINGE, GLASS (50222-346-01) · 50222-346-02
  • 2 CARTON in 1 CARTON (50222-346-04) / 2 SYRINGE, GLASS in 1 CARTON (50222-346-22) / 1 mL in 1 SYRINGE, GLASS (50222-346-01) · 50222-346-04
  • 2 SYRINGE, GLASS in 1 CARTON (50222-346-92) / 1 mL in 1 SYRINGE, GLASS (50222-346-91) · 50222-346-92

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →
Adbry — United States | Molindra Medicines